Bausch Health Companies’ (BHC) Hold Rating Reiterated at Jefferies Financial Group

Bausch Health Companies (NYSE:BHC)‘s stock had its “hold” rating reiterated by equities researchers at Jefferies Financial Group in a report issued on Thursday,Benzinga reports. They currently have a $8.00 target price on the stock, down from their previous target price of $12.00. Jefferies Financial Group’s target price would suggest a potential upside of 22.23% from the company’s current price.

BHC has been the topic of several other reports. StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. Finally, Royal Bank of Canada dropped their price target on shares of Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a research note on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Bausch Health Companies has an average rating of “Hold” and an average target price of $7.42.

Bausch Health Companies Stock Performance

Shares of NYSE BHC traded down $0.80 during midday trading on Thursday, reaching $6.55. 3,312,779 shares of the company traded hands, compared to its average volume of 3,329,603. Bausch Health Companies has a 12 month low of $3.96 and a 12 month high of $11.46. The stock’s 50-day simple moving average is $7.72 and its 200-day simple moving average is $7.46. The firm has a market cap of $2.37 billion, a PE ratio of -13.64 and a beta of 0.68.

Hedge Funds Weigh In On Bausch Health Companies

Several institutional investors have recently modified their holdings of the business. Goldentree Asset Management LP boosted its holdings in Bausch Health Companies by 31.0% during the third quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock worth $239,552,000 after purchasing an additional 6,958,717 shares during the last quarter. Bank of Montreal Can raised its stake in shares of Bausch Health Companies by 234.0% during the 3rd quarter. Bank of Montreal Can now owns 3,833,179 shares of the company’s stock worth $31,598,000 after purchasing an additional 2,685,675 shares in the last quarter. Maple Rock Capital Partners Inc. acquired a new position in Bausch Health Companies during the third quarter worth $16,850,000. SG Americas Securities LLC increased its stake in shares of Bausch Health Companies by 62.0% during the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock worth $26,614,000 after purchasing an additional 1,263,706 shares during the last quarter. Finally, LMR Partners LLP bought a new position in Bausch Health Companies during the third quarter worth about $3,264,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.